AI Science Tracker
EN

Portfolio analysis of single-cell RNA-sequencing and transcriptomic data unravels immune cells and telomere-related biomarkers in sepsis.

Affiliation not stated in the reviewed material · 30 Oct 2025 · medicine

Discovery

Portfolio analysis of single-cell RNA-sequencing and transcriptomic data unravels immune cells and telomere-related biomarkers in sepsis.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: The article combines 101 ML algorithm combinations, transcriptomic and single-cell data to identify four sepsis biomarkers, then checks expression by RT-qPCR in clinical samples. This supports an exploratory sepsis biomarker result; the candidates and drug prediction do not establish clinical utility or causality.

Technology: Full text specifies the learned operation and how it supports the represented result.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Full text specifies the learned operation and how it supports the represented result.
Limitation / still unknown
The four candidate markers and drug-response predictions come from transcriptomic and single-cell analyses; RT-qPCR checks expression in clinical samples but does not establish causal biology or clinical utility.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1638156/full · https://europepmc.org/article/MED/41246299

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.